Vistagen Therapeutics Inc
For the period ended Mar 31, 2024. Filed Jun 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 11, 2024
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · TreasuryStock · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||||||
| Balance at March 31, 2022 | 6,889,400 | $7 | $336,281 | $(3,968) | $(267,604) | $64,716 | |||||||||
| Stock-based compensation expense | — | — | 3,336 | — | — | 3,336 | |||||||||
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 5,167 | 63 | — | — | 63 | ||||||||||
| Issuance of common stock upon exercise of options (cashless) | 3,646 | — | — | — | — | — | |||||||||
| Issuance of common stock upon exercise of options for cash | 3,700 | — | 104 | — | — | 104 | |||||||||
| Increase in fair value attributed to warrant modifications | — | — | 78 | — | — | 78 | |||||||||
| Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses | 413,670 | — | 3,031 | — | — | 3,031 | |||||||||
| Net loss | — | — | — | — | (59,248) | (59,248) | |||||||||
| Balance at March 31, 2023 | 7,315,583 | 7 | 342,893 | (3,968) | (326,852) | 12,080 | |||||||||
| Stock-based compensation expense | — | — | 2,182 | — | — | 2,182 | |||||||||
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 4,843 | — | 8 | — | — | 8 | |||||||||
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 4,698,495 | 5 | 35,894 | — | — | 35,899 | |||||||||
| Issuance of common stock and pre-funded warrants through public offering, net of issuance costs | 15,010,810 | 15 | 93,464 | — | — | 93,479 | |||||||||
| Net loss | — | — | — | — | (29,362) | (29,362) | |||||||||
| Balance at March 31, 2024 | 27,029,731 | $27 | $474,441 | $(3,968) | $(356,214) | $114,286 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.